Medizinische Klinik

, Volume 92, Supplement 4, pp 16–22 | Cite as

Docetaxel in der Behandlung anderer solider Tumoren

  • Albrecht Kretzschmar
  • Claus -Henning Köhne
  • Bernd Dörken
Übersicht

Zusammenfassung

Studienauswertung: Docetaxel (Taxotere®; Rhône-Poulenc Rorer) wurde in der ersten Hälfte der neunziger Jahre bei einem breiten Spektrum von Tumoren untersucht. In den 32 Phase-II-Studien aus Europa, Nordamerika und Japan, auf deren Ergebnisse sich diese Übersicht im wesentlichen bezieht, wurden die folgenden Tumorarten behandelt: Kopf-Hals-Tumoren, Ovarial- und Zervixkarzinome, Weichteilsarkome, gastrointestinale Adenokarzinome, Nieren- und Urothelkarzinome sowie das Melanom und Glioblastom. Aktuelle Ergebnisse von Studien, die eine hohe Effektivität einer Kombinationschemotherapie mit Cisplatin sowohl beim unvorbehandelten Kopf-Hals-Karzinom als auch beim Ovarialkarzinom aufzeigten, werden ebenso referiert.

Ergebnisse: Eine bemerkenswerte Wirksamkeit der Substanz als Monotherapie zeigte sich in der Palliativtherapie nach Rezidiv von Kopf-Hals-Karzinomen (Ansprechrate 27 bis 42%) sowie beim Versagen einer platinhaltigen Therapie beim fortgeschrittenen Ovarialkarzinom, wo die Effektivität von Docetaxel mit der von Paclitaxel oder Topotecan vergleichbar zu sein scheint. Eine vielversprechende antineoplastische Aktivität konnte außerdem beim Magen-, Pankreas- und Urothelkarzinom sowie dem malignen Melanom in mehreren Studien beobachtet werden.

Schlußfolgerung: Docetaxel erwies sich als neues Zytostatikum mit einem breiten Wirkungsspektrum bei den verschiedensten soliden Tumoren. Sein Stellenwert im direkten Vergleich zu etablierten Behandlungsschemata sowie im Rahmen von Kombinationschemotherapien sollte deshalb in weiteren Studien untersucht werden.

Schlüsselwörter

Docetaxel Phase-II-Studien Kopf-Hals-Tumoren Ovarialkarzinom Gastrointestinale Karzinome Weichteilsarkome Melanom Kombinationschemotherapie 

Docetaxel in the treatment of other tumors

Summary

Phase-II-Studies: Docetaxel (Taxotere®; Rhône-Poulenc Rorer) was evaluated in the treatment of a wide range of tumors in the early nineties. This overview relates mainly to the results of 32 phase-II-studies from Europe, North America and Japan including the following malignancies: head and neck cancer, cancer of the ovary and cervix uterus, soft tissue sarcomas, gastrointestinal cancers, renal and transitional cell cancer as well as melanoma and glioma. Results of recent studies also revealed a high activity of combination chemotherapy with cisplatinum in untreated head and neck cancer as well as ovarian cancer.

Results: A remarkable single agent activity was observed in the palliative treatment after recurrence of head and neck tumors (ORR 27 to 42%) and as slavage chemotherapy after failure of platinum compounds in ovarian cancer, where Docetaxel appeared to be similarly active as Paclitaxel and Topotecan. Remarkable activity was also observed in the treatment of gastric, pancreatic and urothelial cancer as well as melanoma.

Conclusion: Docetaxel ist a new cytotoxic drug with a broad range of activity in various solid tumors. The place of this compound in relation to established regimens and its value in combination chemotherapy warrants further investigation.

Keywords

Docetaxel Phase-II-studies Head and neck tumors Ovarian cancer Gastrointestinal cancers Soft tissue sarcoma, Melanoma Combination chemotherapy 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Aamdal, S., I. Wolff, S. Kaplan, R. Paridaens, J. Kerger, J. Schachter, J. Wanders, H. R. Franklin, J. Verweij: Docetaxel (Taxotere) in advanced malignant melanoma: a phase II study of the EORTC Early Clinical Trials Group. Europ. J. Cancer 30-A (1994), 1061–1064.CrossRefGoogle Scholar
  2. 2.
    Abbruzzese J., D. Evans, D. Gravel, A. Markowitz, Y. Patt, R. Pazdur: Docetaxel (D), a potentially active agent for patients with pancreatic adenocarcinomas (PA). Proc. ASCO 14 (1995), 221.Google Scholar
  3. 3.
    Anonymous: Taxotere, International Product Monograph. 2nd ed. Rhône-Poulenc Rorer; Anthony, France 1995.Google Scholar
  4. 4.
    Bedikian, A. Y., G. R. Weiss, S. S. Legha, H. A. Burris III, J. R. Eckardt, J. Jenkins, O. Eton, A. C. Buzaid, L. Smetzer, D. Von Hoff: Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapy. J clin. Oncol. 13 (1995), 2895–2899.PubMedGoogle Scholar
  5. 5.
    Blackstein M., E. Eisenhauer, V. Bramwell, K. Belanger, S. Verma, S. Beare: Docetaxel (Taxotere) as first line therapy for metastatic or recurrent soft tissue sarcoma: a phase II trial. Europ. J. Cancer 31-A, Suppl. 5 (1995), 177.CrossRefGoogle Scholar
  6. 6.
    Blaney, S., N. L. Seibel, M. Obrien, G. H. Reaman, S. Berg, P. Adamson, D. Poplack, M. Krailo, R. Mosher, F. Balis: Phase I trial of docetaxel administered as a 1 hour infusion in children with refractory solid tumors. J. clin. Oncol. 15 (1997), 1538–1543.PubMedGoogle Scholar
  7. 7.
    Bruntsch, U., B. Heinrich, S. B. Kaye, P. H. de Mulder, A. van Oosterom, R. Paridaens, J. B. Vermorken, J. Wanders, H. Franklin, M. Bayssas et al.: Docetaxel (Taxotere) in advanced renal cell cancer. A phase II trial of the EORTC Early Clinical Trials Group. Europ. J. Cancer 30-A (1994), 1064–1067.CrossRefGoogle Scholar
  8. 8.
    Burris, H., M. Moore, J. Anderson, M. Green, M. Rothenberg, M. Modiano, M. Cripps, R. Portenoy, R. Nelson, F. Dorr, S. Stephens, D. von Hoff: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreatic cancer: a randomized trial. J. clin. Oncol. 15 (1997), 2403–2413.PubMedGoogle Scholar
  9. 9.
    Catimel, G., J. Verweij, V. Mattijssen, A. Hanauske, M. Piccart, J. Wanders, H. Franklin, N. Le Bail, M. Clavel, S. B. Kaye: Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group. Ann. Oncol. 5 (1994), 533–537.PubMedGoogle Scholar
  10. 10.
    Clark T., N. Kemeny, J. Conti, M. André: Phase-II-trial of docetaxel in previously untreated patients with advanced colorectel cancer. Proc. ASCO 13 (1994), 212.Google Scholar
  11. 11.
    Constenla, D., M. Hill, A. A’Hern, J. Henk, P. Rhys-Evans, N. Breach, D. Archer, M. Gore: Chemotherapy for symptom control in recurrent squamous cell carcinoma of the head and neck. Ann. Oncol. 8 (1997), 445–449.PubMedCrossRefGoogle Scholar
  12. 12.
    Cortes, J. E., R. Pazdur: Docetaxel. J. clin. Oncol. 13 (1995), 2643–2655.PubMedGoogle Scholar
  13. 13.
    Couteau, C., S. Leyvraz, D. Oulid-Aissa, A. Lebecq, N. Chouaki, C. Domenge, M. De Forni, J. Armand: A phase II study of docetaxel in squamous cell carcinoma of the head and neck. Proc. ASCO 15 (1996), 315.Google Scholar
  14. 14.
    De Wit R., G. Stoter, C. Blanc, S. Hubert, J. Verweij: Phase II study of first-line docetaxel (taxotere) in patients with metastatic urothelial cancer. Ann. Oncol. 5, Suppl. 8 (1994), 67.Google Scholar
  15. 15.
    Dreyfuss, A. I., J. R. Clark, C. M. Norris, R. M. Rossi, J. W. Lucarini, P. M. Busse, M. D. Poulin, L. Thornhill, R. Costello, M. R. Posner: Docetaxel: an active drug for squamous cell carcinoma of the head and neck. J. clin. Oncol. 14 (1996), 1672–1678.PubMedGoogle Scholar
  16. 16.
    Dreyfuss, A. I., J. R. Clark, J. E. Wright, C. M. Norris Jr., P. M. Busse, J. W. Lucarini, B. G. Fallon, D. Casey, J. W. Andersen, R. Klein et al.: Continuous infusion high-dose leucovorin with 5-fluorouracil and cisplatin for untreated stage IV carcinoma of the head and neck. Ann. intern. Med. 112 (1990), 167–172.PubMedGoogle Scholar
  17. 17.
    Ebihara S., H. Fujii, Y. Sasaki, Y. Inuyama: A late phase II trial of docetaxel in patients with head and neck cancer. Proc. ASCO 16 (1997), 399a.Google Scholar
  18. 18.
    Edmonson, J. H., L. P. Ebbert, A. G. Nascimento, S. H. Jung, H. McGaw, J. B. Gerstner: Phase II study of docetaxel in advanced soft tissue sarcomas. Amer. J. clin. Oncol. 19 (1996), 574–576.CrossRefGoogle Scholar
  19. 19.
    Einzig, A. I., D. Neuberg, S. C. Remick, D. D. Karp, P. J. O’Dwyer, J. A. Stewart, A. B. Benson III: Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) results of protocol E1293. Med. Oncol. 13 (1996), 87–93.PubMedCrossRefGoogle Scholar
  20. 20.
    Einzig, A. I., L. M. Schuchter, A. Recio, S. Coatsworth, R. Rodriquez, P. H. Wiernik: Phase II trial of docetaxel (Taxotere) in patients with metastatic melanoma previously untreated with cytotoxic chemotherapy. Med. Oncol. 13 (1996), 111–117.PubMedCrossRefGoogle Scholar
  21. 21.
    Forsyth, P., G. Cairncross, D. Stewart, M. Goodyear, N. Wainman, E. Eisenhauer: Phase II trial of docetaxel in patients with recurrent malignant glioma: a study of the National Cancer Institute of Canada Clinical Trials Group. Invest. New Drugs 14 (1996), 203–206.PubMedCrossRefGoogle Scholar
  22. 22.
    Francis, P., J. Schneider, L. Hann, C. Balmaceda, R. Barakat, M. Phillips, T. Hakes: Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer. J. clin. Oncol. 12 (1994), 2301–2308.PubMedGoogle Scholar
  23. 23.
    Jakobsen E., K. Bertelsen, L. Madsen, A. Jacobsen: Phase I–II study in advanced ovarian cancer with docetaxel (Taxotere), cisplatin and cyclophosphamide. Proc. ASCO 16 (1997), 371a.Google Scholar
  24. 24.
    Janinis J., M. Papadakou, C. Panagos, C. Boukis, E. Xidakis: A phase II study of combined chemotherapy with docetaxel, cisplatin and 5-fluorouracil in patients with advanced squamous cell carcinoma of the head and neck and nasopharyngeal carcinoma. Proc. ASCO 16 (1997), 402a.Google Scholar
  25. 25.
    Kaye, S. B., M. Piccart, M. Aapro, J. Kavanagh: Docetaxel in advanced ovarian cancer: preliminary results from three phase II trials. EORTC Early Clinical Trials Group and Clinical Screening Group, and the MD Anderson Cancer Center. Europ. J. Cancer 31-A, Suppl. 4 (1995), S14–17.CrossRefGoogle Scholar
  26. 26.
    Kudelka, A. P., C. F. Verschraegen, T. Levy, C. L. Edwards, A. Fishman, R. S. Freedman, A. Kaplan, D. G. Kieback, R. Mante, K. Ende, M. Steger, J.J. Kavanagh: Preliminary report of the activity of docetaxel in advanced or recurrent squamous cell cancer of the cervix. Anticancer Drugs 7 (1996), 398–401.PubMedCrossRefGoogle Scholar
  27. 27.
    Lefebvre, J. L., D. Chevalier, B. Luboinski, A. Kirkpatrick, L. Collette, T. Sahmoud: Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J. nat. Cancer Inst. 88 (1996), 890–899.PubMedCrossRefGoogle Scholar
  28. 28.
    McCaffrey, J., S. Hilton, N. Mazumdar, S. Sadan, W. Kelly, H. Scher, D. F. Bajorin: Phase-II-trial of docetaxel in patients with advanced or metastatic transitional cell carcinoma. J. clin. Oncol. 15 (1997), 1853–1857.PubMedGoogle Scholar
  29. 29.
    McGuire, W. P., W. J. Hoskins, M. F. Brady, P. R. Kucera, E. E. Partridge, K. Y. Look, D. L. Clarke Pearson, M. Davidson: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New Engl. J. Med. 334 (1996), 1–6.PubMedCrossRefGoogle Scholar
  30. 30.
    Mertens, W. C., E. A. Eisenhauer, J. Jolivet, S. Ernst, M. Moore, A. Muldal: Docetaxel in advanced renal carcinoma. A phase II trial of the National Cancer Institute of Canada Clinical Trials Group. Ann. Oncol. 5 (1994), 185–187.PubMedGoogle Scholar
  31. 31.
    Morton, R. P., F. Rugman, E. B. Dorman, P. J. Stoney, J. A. Wilson, M. McCormick, A. Veevers, P. M. Stell: Cisplatinum and bleomycin for advanced or recurrent squamous cell carcinoma of the head and neck: a randomised factorial phase III controlled trial. Cancer Chemother. Pharmacol. 15 (1985), 283–289.PubMedCrossRefGoogle Scholar
  32. 32.
    Noda, K., Y. Terajima, Y. Ogita, I. Kono, K. Hirabayashi, M. Yakushiji, T. Taguchi: [Phase II clinical study of RP56976 (docetaxel) in patients with carcinoma ovarii or carcinoma colli uteri]. Gan To Kagaku Ryoho 21 (1994), 2471–2477.PubMedGoogle Scholar
  33. 33.
    Pazdur, R., Y. Lassere, L. T. Soh, J. A. Ajani, B. Bready, E. Soo, S. Sugarman, Y. Patt, J. L. Abbruzzese, B. Levin: Phase II trial of docetaxel (Taxotere) in metastatic colorectal carcinoma. Ann. Oncol. 5 (1994), 468–470.PubMedGoogle Scholar
  34. 34.
    Piccart, M. J., M. Gore, W. Ten Bokkel Huinink, A. van Oosterom, J. Verweij, J. Wanders, H. Franklin, M. Bayssas, S. Kaye: Docetaxel: an active new drug for treatment of advanced epithelial ovarian cancer. J. nat. Cancer Inst. 87 (1995), 676–681.PubMedCrossRefGoogle Scholar
  35. 35.
    Posner M., C. Norris, A. Colevas, R. Tishler, R. Rossi, R. Costello, J. Anderson, M. Poulin, L. Thornhill, P. Busse: Phase I/II trial of docetaxel, cisplatin, 5-fluorouracil and leucovorin (TPFL) for curable, localy advanced squamous cell cancer of the head and neck. Proc. ASCO 16 (1997), 387a.Google Scholar
  36. 36.
    Rougier, P.: Docetaxel delivers new management opportunities for gastrointestinal carcinomas. Anticancer Drugs 6, Suppl. 4 (1995), 25–29.PubMedCrossRefGoogle Scholar
  37. 37.
    Schantz, S., L. Harrison, A. Forastiere: Tumors of the nasal cavity and paranasal sinuses, nasopharynx, oral cavity, and oropharynx. In: De Vita, V. J., S. Hellmann, S. Rosenberg: Cancer: principels and practice of oncology, 5th ed. Lippincott-Raven Publishers, lPhiladelphia 1997, p. 741–799.Google Scholar
  38. 38.
    Schöffski P., J. Wanders, G. Catimel, B. Heinrich, D. Schrijvers, M. Gore, D. Oulid-Aissa, J. Verweij: A promising regimen for treatment of squamous cell carcinoma of the head and neck: docetaxel and cisplatin. Ann. Oncol. 7, Suppl. 5 (1996), 79.Google Scholar
  39. 39.
    Sternberg, C. N., W. W. ten Bokkel Huinink, J. F. Smyth, V. Bruntsch, L. Y. Dirix, N. A. Pavlidis, H. Franklin, S. Wanders, N. Le Bail, S. B. Kaye: Docetaxel (Taxotere), a novel taxoid, in the treatment of advanced colorectal carcinoma: an EORTC Early Clinical Trials Group Study. Brit. J. Cancer 70 (1994), 376–379.PubMedGoogle Scholar
  40. 40.
    Sulkes, A., J. Smyth, C. Sessa, L. Y. Dirix, J. B. Vermorken, S. Kaye, J. Wanders, H. Franklin, N. LeBail, J. Verweij: Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group. Brit. J. Cancer 70 (1994), 380–383.PubMedGoogle Scholar
  41. 41.
    Taguchi, T.: [An early phase II clinical study of RP56976 (docetaxel) in patients with cancer of the gastrointestinal tract]. Gan To Kagaku Ryoho 21 (1994), 2431–2437.PubMedGoogle Scholar
  42. 42.
    Taguchi, T.: A late phase II study of docetaxel in patients with gastric cancer. Proc. ASCO 16 (1997), 263a.Google Scholar
  43. 43.
    The Department of Veterans Affairs Laryngeal Cancer Study Group: Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. New Engl. J. Med. 324 (1991), 1685–1690.CrossRefGoogle Scholar
  44. 44.
    Van Hoesel, Q. G., J. Verweij, G. Catimel, M. Clavel, P. Kerbrat, A. T. van Oosterom, J. Kerger, T. Tursz, M. Van Glabbeke, C. van Pottelsberghe et al.: Phase II study with docetaxel (Taxotere) in advanced soft tissue sarcomas of the adult. EORTC Soft Tissue and Bone Sarcoma Group. Ann. Oncol. 5 (1994), 539–542.PubMedGoogle Scholar
  45. 45.
    Vasey, P., S. Eggleton, A. Birt, M. Crawfort, J. Graham, E. Junor, N. Reed, R. Symonds, S. Kaye: A feasebility study of Taxotere-Cisplatin combination for previously untreated advanced epithelial ovarian cancer. Proc. ASCO 16 (1997), 356a.Google Scholar
  46. 46.
    Verschragen, C., A. Kudelka, M. Steger, C. Edwarts, J. Kavanagh: Randomized phase-II-Study of two doses of docetaxel in patients with advanced epithelial ovarian cancer who have failed paclitaxel chemotherapy. Proc. ASCO 16 (1997), 381a.Google Scholar
  47. 47.
    Verweij, J., I. Judson, D. Crowther, W. Ruka, J. Buesa, R. Colemna, E. Di Paola, D. Locci-Tonelli, M. Van Glabbeke, T. Tursz: Randomized study comparing docetaxel (Taxotere) to doxorubicin in previously untreated soft tissue sarcomas. Proc. ASCO 16 (1997), 496a.Google Scholar

Copyright information

© Urban & Vogel 1997

Authors and Affiliations

  • Albrecht Kretzschmar
    • 1
  • Claus -Henning Köhne
    • 1
  • Bernd Dörken
    • 1
  1. 1.Abteilung für Hämatologie, Onkologie und Tumorimmunologie, Robert-Rössle-KlinikMedizinische Fakultät Charité der Humboldt-Universität zu Berlin, Virchow-KlinikumBerlin-Buch

Personalised recommendations